Distinguish early-onset vs late-onset neonatal sepsis in terms of timing and common pathogens; how does this affect empiric therapy?

• A. Early-onset sepsis occurs within 0-72 hours with GBS and E. coli; late-onset after 72 hours with CoNS, Staph aureus, and Gram-negative rods; empiric therapy should be broader early and narrowed by cultures.
• B. Late-onset sepsis occurs within 0-72 hours and commonly involves GBS and E. coli; early-onset occurs after 72 hours.
• C. Empiric therapy should be the same regardless of timing.
• D. Pathogens do not influence empiric therapy.

Answer: (C)

Timing provides a clue to the likely pathogens in neonatal sepsis, and that guides which antibiotics you start with right away.

In early-onset sepsis, which occurs in the first 72 hours of life, the infection is usually acquired from the mother. The most common culprits are group B Streptococcus and Escherichia coli. Because these organisms are the typical targets, the initial empiric regimen is chosen to cover them, commonly using ampicillin to cover GBS (and Listeria with risk factors) plus an aminoglycoside like gentamicin to broaden Gram-negative coverage. The idea is to start broad enough to fight the usual suspects, then narrow once culture results and susceptibilities are known.

In late-onset sepsis, occurring after 72 hours, the pathogens shift toward organisms more often encountered in the NICU or environment, such as coagulase-negative staphylococci, Staphylococcus aureus, and various Gram-negative rods (and sometimes Candida in very high-risk infants). Empiric therapy reflects this shift, typically adding coverage for resistant Gram-positive organisms (for example, vancomycin to address MRSA/CoNS) and maintaining broad Gram-negative coverage with a suitable beta-lactam or anti-pseudomonal agent, tailored to local patterns and the infant’s risk factors. De-escalation occurs once cultures identify the precise pathogen and susceptibilities.

The key idea is that the likely bugs change with the timing of onset, and the initial antibiotic choices should align with those expectations, with adjustments made as lab results come back.